RNF43 and neoplasm: Indeed, our analysis identified several potential targets such as RNF43 (Wnt-pathway inhibitors), ERBB2 (HER2 targeted therapies), and potentially new dual RAS/RAF inhibitors targeting KRAS. Assessing the efficacy of targeted therapies specifically for this tumor type will be challenging given its rarity, such that basket trials assessing specific targets may be more practical and will be crucial to improve outcomes for women with advanced or recurrent MOC.